Physician profile
Peter Illei
NPI 1720071459
$160,401.62
in general payments reported to CMS, 2019-2025
16 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $28K · 2021: $13K · 2022: $50K · 2023: $22K · 2024: $13K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,200 · Travel and Lodging: $3,377 · Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,186.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,200.00 |
| Travel and Lodging | $3,376.85 |
| Food and Beverage | $1,335.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $51,181.33 | 2019-2024 | Imfinzi, Tagrisso |
| Lilly USA, LLC | $22,549.74 | 2022 | |
| Genzyme Corporation | $17,010.35 | 2022-2023 | |
| Veran Medical Technologies, INC. | $14,946.35 | 2019-2021 | |
| Abbvie INC. | $13,632.43 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,639.62 | 2024-2025 | |
| Astrazeneca Uk Limited | $8,470.00 | 2020-2023 | Enhertu |
| Agilent Technologies, INC. | $6,194.49 | 2023 | |
| Roche Diagnostics Corporation | $5,579.15 | 2019 | |
| Genentech USA, INC. | $3,522.33 | 2022 | |
| Hoffmann-La Roche Limited | $2,118.75 | 2022 | |
| Janssen Scientific Affairs, LLC | $2,020.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,185.00 | 2021 | |
| Daiichi Sankyo INC. | $188.10 | 2024 | Enhertu |
| Intuitive Surgical, INC. | $88.47 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75.51 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Illei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.